Steven Nichtberger

[Cabaletta Bio @CabalettaBio]

Cabaletta Bio receives Fast Track Designation from the @US_FDA for its lead candidate, DSG3-CAART, for the treatment of patients with mucosal pemphigus vulgaris (mPV) #CAART #autoimmune #celltherapy https://t.co/OfpmAZWdMc

[Cabaletta Bio @CabalettaBio]

We are hiring! Please visit us at https://t.co/PYVBdwXpB3 to learn how you can join the #CabalettaCrew

[John D Carroll @JohnCendpts]

This could be big --
Penn spinout preps for human studies of a new-model CAAR, aiming at a one-time cure for autoimmune diseases
https://t.co/5TFZDePH1w

[Bristol Myers Squibb @bmsnews]

Our latest #FDA approval is meaningful in many ways. #LCSM